针对低危妊娠滋养细胞肿瘤（gestational trophoblastic neoplasia，GTN）的治疗，在国际妇产科联盟（FIGO）指南推荐的化疗基础上，应该再次分层，0～4分选择放线菌素-D（Act-D）或甲氨蝶呤（MTX）单药化疗，根据一些研究报道，Act-D的疗效优于MTX，而且副反应发生率更低；5～6分者目前建议单药化疗，但可放宽联合化疗方案的适应证。化疗期间密切监测疗效，如果单药化疗耐药，可以个体化的更换另一种单药或联合方案。

The treatment of low-risk gestational trophoblastic neoplasia，based on the chemotherapy recommended by FIGO guidelines，should be stratified again，and actinomycin D（Act-D）or methotrexate（MTX） single-agent chemotherapy should be selected for those of 0-4 points. According to some research reports，the efficacy of Act-D is better than that of MTX，and the side effects are lower；single-agent chemotherapy is recommended for those with a score of 5-6，but the indications for combined chemotherapy can be broadened. The curative effect should be closely monitored during chemotherapy，and if the single-agent chemotherapy is resistant，another single-agent or combination regimen can be used individually.